Preventing Staphylococcus aureus Sepsis through the Inhibition of Its Agglutination in Blood by McAdow, Molly et al.
Preventing Staphylococcus aureus Sepsis through the
Inhibition of Its Agglutination in Blood
Molly McAdow, Hwan Keun Kim, Andrea C. DeDent, Antoni P. A. Hendrickx, Olaf Schneewind*,
Dominique M. Missiakas
Department of Microbiology, University of Chicago, Chicago, Illinois, United States of America
Abstract
Staphylococcus aureus infection is a frequent cause of sepsis in humans, a disease associated with high mortality and
without specific intervention. When suspended in human or animal plasma, staphylococci are known to agglutinate,
however the bacterial factors responsible for agglutination and their possible contribution to disease pathogenesis have not
yet been revealed. Using a mouse model for S. aureus sepsis, we report here that staphylococcal agglutination in blood was
associated with a lethal outcome of this disease. Three secreted products of staphylococci - coagulase (Coa), von Willebrand
factor binding protein (vWbp) and clumping factor (ClfA) – were required for agglutination. Coa and vWbp activate
prothrombin to cleave fibrinogen, whereas ClfA allowed staphylococci to associate with the resulting fibrin cables. All three
virulence genes promoted the formation of thromboembolic lesions in heart tissues. S. aureus agglutination could be
disrupted and the lethal outcome of sepsis could be prevented by combining dabigatran-etexilate treatment, which
blocked Coa and vWbp activity, with antibodies specific for ClfA. Together these results suggest that the combined
administration of direct thrombin inhibitors and ClfA-antibodies that block S. aureus agglutination with fibrin may be useful
for the prevention of staphylococcal sepsis in humans.
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Introduction
The Gram-positive bacterium Staphylococcus aureus is the
causative agent of human skin and soft tissue infections, invasive
disease and bacteremia [1]. Staphylococcal bacteremia leads to
endocarditis and sepsis, diseases that, even under antibiotic
therapy, are associated with high mortality [2]. Community- and
hospital-acquired infections are frequently caused by antibiotic
(methicillin)-resistant S. aureus (MRSA) [3], resulting in poor
disease outcomes following the failure of antibiotic therapy [4]. A
preventive strategy that can reduce the burden and improve the
outcomes of S. aureus sepsis is therefore urgently needed [5].
S. aureus is a unique disease pathogen owing to its multiple
interactions with fibrinogen [6,7,8], a highly abundant host
protein responsible for the formation of fibrin clots following
cleavage by thrombin [9]. Fibrinogen is a glycoprotein with Mr
,340,000, formed by three pairs of Aa-, Bb-, and c-chains
covalently linked to form a ‘‘dimer of trimers,’’ where A and B
designate the fibrinopeptides released by thrombin cleavage [10].
The elongated molecule folds into three separate domains, a
central domain E that contains the N-termini of all six chains and
two flanking domains D formed mainly by the C-termini of the
Bb- and c-chains [9]. These globular domains are connected by
long triple-helical structures [9].
S. aureus secretes two coagulases, Coa and von-Willebrand factor
binding protein (vWbp), polypeptides that also promote cleavage
of the Aa and Bß chains of fibrinogen to generate fibrin clots [11].
Coagulases conformationally activate the central coagulation
zymogen prothrombin [10]. The crystal structure of the active
complex revealed binding of the D1 and D2 domains of coagulases
to prothrombin and insertion of their Ile
1-Val
2 N-terminus into
the Ile
16 pocket of the zymogen, inducing a functional active site
through conformational change [11]. Exosite I of a-thrombin, the
fibrinogen recognition site, and proexosite I on prothrombin are
blocked by the D2 of Coa [11]. Nevertheless, association of the
tetrameric (Coa?prothrombin)2 complex enables fibrinogen bind-
ing at a new site with high affinity [10]. This model explains the
coagulant properties and efficient fibrinogen conversion by
coagulases [10]. S. aureus mutants lacking both coagulases, coa
and vwb, are unable to form abscesses in a mouse model of
staphylococcal diseases [12]. When used as a purified antigen, Coa
and vWbp elicit protective immune responses that prevent the
formation of abscesses in the same model [12].
The coagulation of calcium-chelated plasma following incuba-
tion with bacteria [12] is still used in clinical laboratories to
distinguish S. aureus isolates from non-pathogenic staphylococci
(coagulase test) [13]. Another diagnostic tool, the slide agglutina-
tion test, monitors the agglutination of S. aureus immersed in
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physiological relevance of staphylococcal agglutination are not yet
known. S. aureus strains express clumping factor A (ClfA) [15], a
surface protein that promotes precipitation of staphylococci
through association with soluble fibrinogen (clumping reaction)
[16,17,18]. The N2 and N3 domains of ClfA (residues 229–545)
bind to the C-terminal end of the fibrinogen c-chains (residues
395–411) [19,20]. S. aureus mutants lacking functional clfA display
virulence defects in mouse models for septic arthritis or
endocarditis, phenotypes that have been attributed to the loss of
staphylococcal binding to fibrinogen deposited on inflamed joint
tissues or on mechanically damaged heart valves [21,22]. ClfA also
contributes to staphylococcal escape from phagocytic killing,
which involves its binding to complement regulatory factor I [23].
A ClfA-specific monoclonal antibody has been isolated that blocks
staphylococcal association with the fibrinogen c-chain [24]. A
phase II clinical trial with bacteremic patients compared the
efficacy of monoclonal antibody (Tefibazumab) and antibiotic
treatment with placebo and antibiotic. However, composite
clinical end point analysis did not detect differences between
placebo and antibody [25].
Birch-Hirschfeld employed a biochemical approach to elucidate
S. aureus agglutination in citrate-plasma and proposed a reaction
pathway involving both fibrinogen and prothrombin [26]. This
work suggests a considerably more complex mechanism for S.
aureus agglutination rather than the direct association of bacteria
with fibrinogen (clumping). To explore this possibility, we have
searched for staphylococcal mutants that are defective for
agglutination and/or sepsis with the purpose of identifying new
preventive strategies for this disease.
Results
Surface proteins contribute to staphylococcal sepsis
We previously developed an animal model to examine the
genetic requirements for staphylococcal sepsis [27]. Briefly, S.
aureus Newman, 1610
8 CFU, is injected into the retro-orbital
plexus of BALB/c mice, resulting in 100% lethality over a ten day
observation period [27]. This model was used to examine the
contribution of secreted coagulases to staphylococcal sepsis [12]. S.
aureus Newman mutants lacking the coa and vwb genes displayed
increased time-to-death and increased survival phenotypes
[12](Table 1). Earlier work identified sortase A (SrtA), an enzyme
that links surface proteins to the staphylococcal cell wall envelope
[28], as an essential virulence factor for sepsis [27]. Nevertheless,
these studies left unresolved which surface protein(s) play a key role
in this disease process. S. aureus mutants with insertional lesions in
any one of eighteen surface protein genes [29] were tested for their
role in sepsis (Table 1). These experiments identified clumping
factor A (ClfA) as the single most important contributor (Table 1).
Although mutations in clfA diminished the severity of clinical
disease and improved the outcome of sepsis, clfA mutants retained
significant virulence and were still capable of killing infected
animals, unlike srtA variants (Table 1).
Genetic requirements for staphylococcal agglutination
S. aureus Newman mutants with defined genetic lesions [29]
were screened for defects in agglutination (Fig. 1A). Mutations that
abrogated the secretion of only one of the two coagulases, Coa
[30] or vWbp [31], had little or no effect on agglutination (Fig.
1AB). In contrast, a mutant lacking both genes (coa/vwb) was
severely impaired for agglutination, similar to a clfA variant (Fig.
1AB). A mutant lacking all three genes - coa, vwb, and clfA - was
unable to agglutinate in plasma (Fig. 1AB). Mutants with
insertional lesions in other known fibrinogen binding proteins,
efb [32,33] and clfB [34], did not cause large defects in
agglutination (Fig. 1AB). The phenotypic agglutination defects of
coa/vwb as well as clfA mutants could be restored by transformation
Table 1. Surface protein genes and their contribution to
S. aureus sepsis.
Genotype P values
Median survival time
(hours ± SEM)
wild-type - 24 (1.6)
srtA ,0.0001 .240
sasF 1.000 24 (1.6)
sdrC 0.5416 24 (1.2)
sdrD 0.5416 24 (1.2)
sasD 0.3415 24 (2.0)
isdA 0.3116 24 (1.8)
sasG 0.1462 24 (0)
clfB 0.0888 24 (1.2)
sdrE 0.0888 24 (4.8)
isdH 0.0143 24 (2.0)
isdB 0.0243 30 (3.2)
sasA 0.0004 36 (7.3)
isdC ,0.0001 36 (1.2)
vwb ,0.0001 36 (2.6)
fnbpA 0.0004 48 (5.5)
sasB ,0.0001 48 (7.4)
sasC 0.0011 54 (8.8)
fnbpB ,0.0001 60 (8.0)
coa ,0.0001 72 (12.5)
adsA ,0.0001 96 (16.7)
clfA ,0.0001 120 (15.3)
BALB/c mice were infected by retro-orbital injection with 1610
8 CFU of
S. aureus Newman or its variants with insertional lesions in either sortase A (srtA)
or any one of eighteen genes encoding sortase A-anchored surface proteins or
the two coagulase genes, coa and vwb. Median survival time represents the
time at which 50% of infected mice (n=10) exhibited lethal disease. Statistical
significance was determined by the two-tailed Logrank test. Data are
representative of two independent experiments.
doi:10.1371/journal.ppat.1002307.t001
Author Summary
Staphylococcus aureus secretes factors that perturb blood
coagulation in infected hosts. We report here that three
bacterial products – coagulase (Coa), von Willebrand factor
binding protein (vWbp) and clumping factor (ClfA) - act
together and promote agglutination, the association of
staphylococci with polymerized fibrin cables. Staphylococ-
cal agglutination was associated with thromboembolic
lesions in heart tissues and a lethal outcome of S. aureus
sepsis in mice. Inhibition of Coa and vWbp with direct
thrombin inhibitors, drugs already approved for the
prevention of stroke, as well as passive transfer of
antibodies specific for Coa, vWbp and ClfA could prevent
the pathogenesis of S. aureus sepsis. These results suggest
new preventive and/or therapeutic strategies that may
improve the outcome of S. aureus sepsis in humans, a
disease that is otherwise associated with high mortality.
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encoding wild-type alleles to the corresponding mutational lesions
(Fig. 1C). Thus, unlike ClfA-mediated clumping of staphylococci
via binding to fibrinogen [15], S. aureus agglutination appears to be
a multi-factorial process involving coagulases, ClfA, as well as
fibrinogen and prothrombin [26].
Staphylococcal agglutination in septic mice
To test whether staphylococcal agglutination occurred in mice
with sepsis, the hearts of animals that had succumbed to S. aureus
Newman challenge were examined for histopathology (Fig. 2).
Deposits of large numbers of staphylococci, mostly without
immune cell infiltrates, were identified in hematoxylin-eosin
stained heart tissue twelve hours after infection (Fig. 2A–D). The
appearance of these staphylococcal agglutinations is consistent
with the general concept of thromboembolic deposition of S. aureus
during sepsis [35] (Fig. 2A). Immuno-histochemical staining was
used to detect specific agglutination factors (Fig. 2E). These
experiments identified prothrombin and fibrinogen (fibrin) in the
immediate vicinity of staphylococcal agglutinations (Fig. 2E). In
agreement with the hypothesis that agglutination contributes to
the pathogenesis of sepsis, fewer heart lesions were observed when
mice were challenged with either clfA or coa/vwb variants (Fig. 3).
Of note, heart tissues of animals necropsied twelve hours after
intravenous challenge harbored considerable loads of staphylo-
cocci, irrespective of the challenge strain. Nevertheless, histopa-
thology features of heart lesions associated with clfA or coa/vwb
variants revealed immune cell infiltrates in the absence of
staphylococcal agglutinations (Fig. 3B). A mutant lacking all three
agglutination factors - clfA, coa and vwb - failed to generate either
immune cell infiltrates or S. aureus agglutinations in heart tissues
(Fig. 3B) and appeared avirulent in the mouse sepsis model
(Fig. 3C).
Clumping factor A tethers staphylococci to fibrin cables
Staphylococcal agglutination requires coagulase catalyzed
conversion of fibrinogen to fibrin as well as ClfA-mediated
attachments. If so, ClfA may bind not only fibrinogen but also
Figure 1. Staphylococcus aureus agglutination in citrate-plasma is a multi-factorial process and essential for the pathogenesis of
sepsis in mice. (A) Agglutination in EDTA-plasma of Syto-9 stained S. aureus Newman wild-type (wt) or its isogenic mutants with insertional lesions
in single or multiple genes: coa (coagulase), vwb (von Willebrand factor binding protein), clfA (clumping factor A), clfB and efb (extracellular fibrinogen
binding protein). (B) Quantification of agglutination for staphylococcal mutants (A) expressed as the percent relative to wt (100%). Average and
standard error of the means were calculated from sixteen fields of microscopic view and statistical significance was assessed in pairwise comparison
between wt and mutant with the two-tailed Student’s t-test: *P,0.01, **P,0.0001. (C) Complementation studies of staphylococcal agglutination
using the slide agglutination test. S. aureus Newman variants coa/vwb and clfA were transformed with plasmids pcoa-vwb and pclfA, respectively.
Statistical significance was analyzed by two-tailed Student’s t-test; ***P,0.0001.
doi:10.1371/journal.ppat.1002307.g001
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purified recombinant ClfA to either fibrinogen or fibrin immobi-
lized in wells of polystyrene plates (Fig. 4A). Using non-linear
regression analyses, we calculated a dissociation constant (Kd)o f
395.2 nM (651.82) for ClfA binding to fibrinogen, comparable to
earlier affinity measurements [18]. The Kd of ClfA binding to
fibrin was calculated as 661.9 nM (680.32), which is not
significantly different from the affinity of ClfA for fibrinogen
(Fig. 4A). To further investigate S. aureus Newman interactions
with fibrin, staphylococci were examined by scanning electron
microscopy (SEM), which revealed agglutinated wild-type bacteria
enmeshed in fibrin cables (Fig. 4B). SEM analysis of the
staphylococcal variants coa/vwb and coa/vwb/clfA identified
bacteria without fibrin cables (Fig. 4B). The clfA mutant continued
to convert fibrinogen to fibrin, however clfA variant staphylococci
did not agglutinate with fibrin cables (Fig. 4B). Plasmids pcoa-vwb
and pclfA complemented the phenotypes caused by mutations in
the corresponding genes and restored staphylococcal agglutination
to wild-type levels (Fig. 4B). These data are in agreement with our
general hypothesis that Coa/vWbp-derived fibrin cables provide a
tether for ClfA-mediated staphylococcal agglutination (Fig. 4B).
Antibodies that prevent staphylococcal agglutination
and sepsis
To further explore the contributions of Coa, vWbp and ClfA to
staphylococcal agglutination, we raised rabbit antibodies against
affinity purified recombinant proteins [12,36]. Affinity purified
rabbit antibodies specific for Coa, vWbp or ClfA inhibited S. aureus
Newman agglutination in plasma (Fig. 4C). Passive transfer of
ClfA-specific rabbit antibodies (85 mg purified antigen-specific
IgG) into the peritoneal cavity of mice reduced the deposition of S.
aureus Newman agglutinations in heart tissues of infected animals
(Fig. 5A). Active immunization of mice with purified Coa and
vWbp or ClfA raised specific IgG antibodies and reduced the
frequency of heart lesions in animals challenged for twelve hours
with wild-type S. aureus Newman (Fig. 5B). In particular, the
abundance of staphylococcal agglutinations without immune cell
infiltrates was reduced (Fig. 5B). Active immunization of mice
with all three antigens – Coa, vWbp and ClfA – eliminated
staphylococcal agglutination in heart tissues and caused the largest
reduction of all types of pathological lesions (Fig. 5B). Similar to
Coa- and vWbp-specific immunoglobulin [12], passive transfer of
ClfA-specific rabbit antibodies into the peritoneal cavity of mice
increased the survival time in the sepsis model of infection
(Fig. 4D). These data corroborate the concept that ClfA-specific
antibodies can improve the outcome of S. aureus Newman sepsis
[24].
Direct thrombin inhibitors and staphylococcal sepsis
Univalent direct thrombin inhibitors, e.g. argatroban and
dabigatran, inhibit the proteolytically active Coa?prothrombin
complex [37,38]. We examined whether these inhibitors also block
the catalytic activity of vWbp?prothrombin. As a control,
conversion of fibrinogen to fibrin by thrombin was monitored as
an increase in sample absorbance at 450 nm. Compared to a
mock control, this reaction was blocked with 200 ng argatroban
(Fig. 6A). Treatment of fibrinogen with either Coa?prothrombin or
vWbp?prothrombin led to fibrin conversion, whereas incubation
with prothrombin alone did not (Fig. 6A). Incubation of both
Coa?prothrombin or vWbp?prothrombin with 200 ng argatroban
Figure 2. Staphylococcus aureus agglutination occurs during the pathogenesis of sepsis in mice. (A–D) Quantification of heart lesions in
BALB/c mice (n=10) 12 hours post-infection with S. aureus Newman. Three types of lesions were observed with either (A) staphylococcal
agglutination (SA) without immune cell infiltrates (PMNs, polymorphonuclear leukocytes), (B) immune cell infiltrates without SAs (PMNs only) or (C)
SA with surrounding granulocytes (SA+PMNs). Heart tissues were stained with hematoxylin-eosin and lesions enumerated (D). Error bars represent
standard error of the mean of tissue samples. Data are representative of two independent experiments. (E) Immuno-histochemical analysis of heart
tissues from BALB/c mice (n=10) 12 hours following intravenous challenge with S. aureus Newman. Samples were stained with antibodies directed
against mouse fibrinogen (a-fibrinogen) or mouse prothrombin (a-prothrombin). Arrows point to staphylococcal agglutinations (black) or immune
cell infiltrates (green); scale bars represent 1 mm.
doi:10.1371/journal.ppat.1002307.g002
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troban treatment also interfered with the agglutination of S. aureus
Newman in plasma (Fig. 6B).
To evaluate the efficacy of direct thrombin inhibitors on the
outcome of S. aureus Newman sepsis, mice received intraperitoneal
injections with 10 mg/kg dabigatran-etexilate in 12 hour intervals.
Dabigatran-etexilate is converted in mammalian tissues to its
active form, dabigatran, which acts as a direct inhibitor of
thrombin [39]. To assess dabigatran activity, mouse blood samples
were drawn by cardiac puncture and the dilute thrombin time was
determined (Fig. S1). Following challenge of mice via blood stream
injection of 1610
8 CFU S. aureus Newman, mock treated animals
died of sepsis within 60 hours post challenge (Fig. 6C). In contrast,
dabigatran-etexilate treated animals survived up to 132 hours,
albeit that all animals in this cohort eventually succumbed to the
challenge (Fig. 6C). To determine whether direct thrombin
inhibitors specifically block Coa and vWbp, mock or dabigatran-
etexilate treated animals were challenged with the S. aureus coa/vwb
mutant. In these experiments, dabigatran-etexilate treatment had
no effect on survival or time-to-death (Fig. 6C). Mock or
dabigatran-etexilate treated mice were also infected with lethal
doses of S. aureus USA300 LAC, the current clone responsible for
the epidemic of community-acquired MRSA infections in the
United States [5]. Dabigatran-etexilate treatment prolonged the
survival of septic mice (Fig. 6D).
Inhibiting multiple staphylococcal factors improves the
outcome of sepsis
If clfA, coa and vwb act together to promote S. aureus Newman
agglutination, dabigatran-etexilate treatment would be expected to
improve the outcome of sepsis caused by clfA mutant staphylococci
(Fig. 7A). Indeed, dabigatran-etexilate treatment increased the
survival and time-to-death of mice with sepsis caused by clfA
mutant S. aureus compared to a control strain harboring the
complementing plasmid pclfA (Fig. 7A). Dabigatran-etexilate
treatment further improved the disease outcome of animals
challenged with clfA mutant staphylococci compared to a cohort
of mock treated mice (Fig. 7A). Injection of clfA mutants carrying
pclfA into the blood stream of mice resulted in reduced time-to-
death compared to the wild-type parent, S. aureus Newman
(Fig. 7A). Nevertheless, animals infected with the clfA (pclfA)
variant also benefited from dabigatran-etexilate treatment
(Fig. 7A).
Totestwhethercombiningdabigatran-etexilateandClfA-specific
antibodies can improve the outcome of staphylococcal sepsis,
animalsreceived both treatmentsfollowed bychallengewith a lethal
dose of S. aureus (Fig. 7B). As compared to mock-treated animals or
mice receiving either dabigatran or ClfA-specific antibodies, the
combination of dabigatran and ClfA-specific antibodies led to
increased time-to-death and survival of staphylococcal sepsis
(Fig. 7BC).
We wondered whether the use of thrombin inhibitors and ClfA-
specific antibodies could aid in the prevention of sepsis caused by
clinical S. aureus isolates. To test this, we used the community-
acquired MRSA isolate MW2, which was isolated from a fatal case
of septicemia [40], as well as the hospital-acquired MRSA isolate
N315 [41]. S. aureus strains N315 and MW2 both agglutinated
when suspended in EDTA-plasma (Fig. 8A). These reactions were
inhibited by treatment with argatroban (Fig. 8A) or with ClfA-
specific antibodies (Fig. 8B). Treatment of mice with both
dabigatran and ClfA-specific antibodies led to increased time-to-
death during sepsis caused by either S. aureus N315 or S. aureus
MW2 (Fig. 8CD). In contrast, the use of either dabigatran or ClfA-
specific antibodies alone did not prolong the survival of mice
Figure 3. Staphylococcal agglutination in heart tissues is
required for the pathogenesis of sepsis. (A) Staphylococcal load,
enumerated as colony forming units (CFU), in heart tissues of BALB/c
mice (n=10) 12 hours after retro-orbital inoculation with 10
8 CFU of
S. aureus Newman (wt) or its variant strains (clfA, coa/vwb and coa/vwb/
clfA). Horizontal lines represent mean CFU. Statistical analysis was
performed with the Mann-Whitney test: wt vs. clfA, P=0.0002; wt vs.
coa/vwb, P=0.0002; wt vs. coa/vwb/clfA, P=0.0002; coa/vwb vs. coa/
vwb/clfA, P=0.0007; clfA vs. coa/vwb/clfA, P=0.0002. Data are
representative of two independent experiments. (B) Summary of
histopathology findings in thin-sectioned and hematoxylin-eosin
stained heart tissue from BALB/c mice (n=10) 12 hours after retro-
orbital injection of S. aureus Newman wild-type (wt) or its clfA, coa/vwb
as well as clfA/coa/vwb variants. Representative lesions in heart tissues
included staphylococcal agglutination without PMNs (SA), with PMNs
(SA+PMNs), and PMN accumulation without staphylococcal agglutina-
tion (PMNs–SA). Error bars represent standard error of the mean from
10 hearts. Statistical significance of lesions for each mutant compared
to wt infection was determined by Student’s t test: *P,0.05, **P,0.01,
***P,0.001. Data are representative of two independent experiments.
(C) Survival of cohorts of BALB/c mice (n=20) following intravenous
injection with S. aureus Newman (wt) or variants lacking coa, vwb or
clfA. Data are representative of three independent experiments.
Statistical significance was assessed with the logrank test: wt vs. coa/
vwb (P,0.01), wt vs. clfA (P,0.001), and wt vs. coa/vwb/clfA (P,0.0001).
doi:10.1371/journal.ppat.1002307.g003
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(Fig. 8CD).
Discussion
Sepsis is a clinical condition in response to severe bacterial
infection, which is associated with high mortality due to continued
activation and apoptosis of immune cells and malperfusion of
organ systems [42]. During sepsis, the physiological coordination
between hemostasis and inflammation is dysregulated, triggering
intravascular fibrin deposits [disseminated intravascular coagula-
tion (DIC)] [43]. Dysregulated clotting places sepsis patients at
high risk for systemic bleeding and loss of perfusion for vital organ
systems [42]. Most anticoagulants, including the thrombin
inhibitors heparin, hirudin and antithrombin, cannot alter the
outcome of sepsis, likely because these compounds can halt an
advancing coagulopathy but are unable to reverse the detrimental
effects of established disease [43,44,45]. Activated protein C is a
serine protease that inactivates the clotting cascade factors Va and
VIIIa, without which thrombin-mediated coagulation, i.e. the
conversion of fibrinogen to fibrin, is slowed by 2–3 orders of
magnitude [46]. Recombinant human activated protein C
(drotrecogin alfa) is currently the only FDA-licensed adjunctive
therapy in patients with severe sepsis [47,48]. Clinical trial data
indicate reduced mortality in 6.1% of all cases but also
considerable bleeding risks. Activated protein C may be
particularly useful in preventing sepsis caused by Escherichia coli
or other Gram-negative bacteria [49]. The ability of activated
protein C treatment to affect the outcome of sepsis caused by
different bacterial or fungal pathogens is not known [50].
Invasive S. aureus infections are frequently associated with
bacteremia and may rapidly advance to sepsis [51]. The use of b-
lactam antibiotics is obsolete for the treatment of sepsis with drug-
resistant S. aureus strains (MRSA)[51]. Patients with MRSA
infections typically receive vancomycin [51], a glycopeptide
antibiotic that blocks bacterial cell wall synthesis [52]. Due to
significant nephrotoxicity, vancomycin therapy must be carefully
monitored to exceed the minimal inhibitory concentration for
staphylococci in host tissues yet avoid the detrimental effects of this
compound on kidney function [53]. Even with intensive clinical
care, the annual survival of patients with MRSA sepsis is low
(,50%) [54]. Thus, preventive measures or therapeutics that
Figure 4. ClfA enables staphylococcal agglutination with fibrin cables in vitro and in vivo. (A) The association of purified recombinant ClfA
with immobilized fibrinogen or fibrin was assessed by ELISA and analyzed as the percentage of maximal binding. Average and standard error of the
means were calculated from three independent experiments. Curves represent nonlinear regression for one-site binding saturation performed with
GraphPad Prism, Fbgn R
2=0.9876; Fibrin R
2=0.9876. (B) Scanning electron micrographs of S. aureus Newman (wt) and its isogenic mutants immersed
in plasma. (C) Affinity-purified rabbit IgG specific for Coa (a-Coa), vwb (a-vWb), ClfA (a-ClfA) or the plague protective antigen V10 (a-V10) was
analyzed for its ability to prevent staphylococcal agglutination. Statistical significance of antibody effects compared to a mock treated control was
assessed with the Student’s t test: *P,0.05. (D) BALB/c mice (n=10) were passively immunized by intraperitoneal injection with affinity-purified
antibodies against V10 or ClfA and disease protection assessed by intravenous challenge with S. aureus Newman. Data represent one of three
independent experiments. Statistical significance was assessed with the logrank test: P,0.01.
doi:10.1371/journal.ppat.1002307.g004
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health issue in the United States [51].
S. aureus sepsis isolates coagulate blood and/or agglutinate in
citrate-plasma [2]. Genome sequencing revealed that all clinical S.
aureus isolates harbor functional coa, vwb and clfA genes [55]. In
contrast, only some staphylococcal strains, those carrying hlb-
converting phages, harbor the sak gene [56], whose secreted
product staphylokinase associates with plasminogen to promote
fibrinolysis [57,58] in addition to cleaving human antimicrobial
peptides (defensins)[59]. We wondered whether the unique
attributes of S. aureus to generate fibrin deposits contribute also
to the pathogenesis of sepsis. Using a mouse model for this disease,
we observed that sortase A mutants, unable to anchor any one of
nineteen different surface proteins in the staphylococcal envelope
[60], were unable to cause sepsis [27]. ClfA, a surface protein
associated with bacterial binding to fibrinogen [17], is the most
important sortase A anchored virulence factor for sepsis (Table 1).
Mutations in two coagulases, coa and vwb [12], further diminish the
virulence of clfA mutants to a level that resembles that of sortase A
variants (Fig. 1). To investigate the physiological role of coagulases
and ClfA, we studied staphylococcal agglutination, a clinical
microbiological assay requiring fibrinogen and prothrombin for
bacterial association with fibrin fragments [26]. All three
staphylococcal products - Coa, vWbp and ClfA – were required
to agglutinate the pathogen in blood and cause lethal disease in
mice. We presume that staphylococcal agglutination in vivo
promotes the formation of thromboembolic lesions that contribute
to the rapid lethality of S. aureus Newman [61] or USA300 LAC
infections [62] into the bloodstream of mice.
Pretreatment of animals with dabigatran-etexilate, which blocks
cleavage of fibrinogen by Coa?prothrombin and vWbp?prothrom-
bin, as well as administration of ClfA-specific antibodies both
interfere with S. aureus agglutination and reduce the mortality of
sepsis. Nevertheless, combining direct thrombin inhibitors with
ClfA-specific antibodies or combining anti-ClfA with anti-Coa/
anti-vWbp can generate an even higher level of protection against
sepsis. The recent licensure of direct thrombin inhibitors (e.g.
dabigatran) and the availability of ClfA-specific monoclonal
antibody provide an opportunity for the rapid testing of such
regimen to reduce the incidence and/or the mortality of S. aureus
sepsis.
ClfA binding to the C-terminal residues of the fibrinogen c-
chain may not be involved in S. aureus agglutination; this portion of
the polypeptide is thought to be buried within polymerized fibrin
cables [63,64]. If so, staphylocoagulase mediated cleavage of
fibrinogen may reveal another binding site for ClfA on the surface
of fibrin cables, enabling staphylococcal agglutination in a manner
that can be inhibited with ClfA-specific antibodies. Direct
thrombin inhibitors block coagulase (Coa and vWbp) mediated
cleavage of fibrinogen and thereby hinder the formation of ClfA
binding sites on the surface of fibrin cables. These compounds also
mimic the phenotype of S. aureus Newman coagulase mutants
(Dcoa, vwb) in the murine sepsis model and presumably exert a
similar effect in preventing the formation of staphylococcal
abscess.
S. aureus is a frequent cause of human wound infections [1],
however the contribution of coagulases towards the establishment
of this disease is not known. Of note, physiological hemostasis
during wound healing generates fibrin and platelet deposits within
wounded tissues [65]. Thus, it would be interesting to explore
whether preventive treatment with direct thrombin inhibitors as
well as ClfA-specific antibodies can reduce the incidence of
hospital-acquired sepsis and/or wound infections.
Figure 5. Neutralization of coagulases and ClfA prevents
staphylococcal agglutination in heart tissues of septic mice.
(A) Quantification of histopathology lesions in heart tissues of BALB/c
mice (n=10) passively immunized with affinity-purified V10 control
antibodies (which neutralize the plague protective antigen LcrV) or ClfA
antibodies prior to lethal infection. Hearts were removed during
necropsy 12 hours after retro-orbital inoculation of staphylococci.
Tissues were thin-sectioned, stained with hematoxylin-eosin and
histopathology lesions enumerated. Error bars represent standard error
of the mean from cohorts of ten mice. Statistical analysis was performed
by two-tailed Student’s t-test comparing same lesion types between
mock-immunized and vaccinated animals: *P,0.05, **P,0.01,
***P,0.001. (B) Quantification of three types of histopathology lesions
in heart tissues from mice actively immunized with recombinant Coa,
vWbp, or ClfA. Hearts were removed during necropsy 12 hours after
retro-orbital inoculation of staphylococci into BALB/c mice (n=10).
Tissues were thin-sectioned, stained with hematoxylin-eosin and
histopathology lesions enumerated. Error bars represent standard error
of the mean from cohorts of ten mice. Statistical analysis was performed
by Student’s two-tailed t-test comparing same lesion types between
mock-immunized and vaccinated animals: *P,0.05, **P,0.01,
***P,0.001. Data are representative of two independent experiments.
(C) Half maximal IgG antibody titer specific for Coa, vWb or ClfA
antigens in serum following active vaccination of BALB/c mice (n=5).
Blood samples were drawn at the time of challenge. Error bars
represent standard deviation of serum IgG titers. The limit of detection
is 100.
doi:10.1371/journal.ppat.1002307.g005
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Ethics statement
Animal experiments involving S. aureus challenge followed
protocols that were reviewed, approved and performed under
the regulatory supervision of The University of Chicago’s
Institutional Biosafety Committee (IBC) and the Institutional
Animal Care and Use Committee (IACUC). Animals were
managed by the University of Chicago Animal Resource Center,
which is accredited by the American Association for Accreditation
of Laboratory Animal Care and the Department of Health and
Human Services (DHHS number A3523-01). Animals were
maintained in accordance with the applicable portions of the
Animal Welfare Act and the DHHS ‘‘Guide for the Care and Use
of Laboratory Animals’’. Veterinary Care was under the direction
of full-time resident veterinarians boarded by the American
College of Laboratory Animal Medicine. BALB/c mice and New
Zealand white rabbits were purchased from Charles River
Laboratories and Harlan Sprague Dawley, respectively. After
confirming that the data sets abide by a normal distribution, the
statistical analysis of staphylococcal sepsis was analyzed using the
two-tailed Logrank test. Quantification of mouse heart tissue
histopathology was analyzed for statistical significance using the
unpaired two-tailed Student’s t-test. The bacterial load (CFU) in
heart tissue from mice infected with staphylococcal variants was
analyzed with the Mann Whitney test. The results of all animal
experiments were examined for reproducibility.
Bacterial strains and growth of cultures
S. aureus strains Newman [61], USA300 LAC [62], MW2 [40]
and N315 [41] were cultured on tryptic soy agar or broth at 37uC.
E. coli strains DH5a and BL21 (DE3) were cultured on Luria
Bertani agar or broth at 37uC. Ampicillin (100 mg/ml) and
chloramphenicol (10 mg/ml) were used for pET15b and pOS1
selection [66], respectively.
Transposon mutants and plasmids
Insertional mutations carrying the bursa aurealis transposon with
an erthyromycin resistance cassette from the Phoenix library [29]
were transduced with bacteriophage into S. aureus Newman or the
coa/vwb mutant [12]. Mutations were verified by PCR with specific
primer pairs for coa (CGCGGATCCATAGTAACAAAGGAT-
TATAGTGGGAAATCACAAG and TCCCCCGGGTTATTT-
TGTTACTCTAGGCCCATATGTCGC), vwb (CGCGGATC-
CGTGGTTTCTGGGGAGAAGAATCC and TCCCCCGG-
GTTTGCAGCCATGCATTAATTATTTGCC) and clfA (CGC-
GGATCC-AAGGTCAAATCGACCGTT and CGGGGTACC-
TTATTTCTTATCTTTATTTTCTTTTTTTC) as well as by
immunoblotting with specific rabbit antibodies [12,36]. Comple-
Figure 6. Direct thrombin inhibitors block a key step in staphylococcal pathogenesis. (A) Conversion of fibrinogen to fibrin by
prothrombin, Coa?prothrombin or vwb?prothrombin was detected in the presence or absence of 200 ng argatroban (Agb). Arbitrary units are defined
as A450*100. Average and standard error of the means were calculated from three independent measurements. (B) Agglutination of S. aureus
Newman or S. aureus USA300 LAC in plasma in the presence of increasing concentrations of Agb. Average and standard error of the means were
calculated from three independent measurements and statistical significance was assessed with the Student’s two-tailed t-test: *P,0.05, **P,0.0001.
(C) Survival of cohorts of BALB/c mice (n=15) treated with saline (mock) or dabigatran-etexilate (Dbg) and infected with either S. aureus Newman or
the coa/vwb mutant strain. Statistical significance was analyzed with the logrank test: mock vs. Dbg with wt challenge: P ,0.0001; mock vs. Dbg with
coa/vwb challenge: P=0.43. Data are representative of three independent experiments. (D) Survival of cohorts of BALB/c mice (n=15) treated with
saline (mock) or dabigatran (Dbg) and challenged by intravenous inoculation with S. aureus USA300 LAC. Statistical significance was analyzed
with the logrank test: mock vs. Dbg, P,0.01. Data are representative of three independent experiments.
doi:10.1371/journal.ppat.1002307.g006
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[12,67]. For immunoblot analysis, 1 mL of staphylococcal
overnight cultures grown in tryptic soy broth (Difco) were
centrifuged at 8,0006g for 3 min in a table top centrifuge and
the supernatant was recovered. Proteins in culture supernatants
were precipitated with 10% trichloroacetic acid on ice for 20
minutes. Pellets were washed once in 1 mL TSM (100 mM Tris-
HCl, pH 7.5, 0.5 M sucrose, 10 mM MgCl2), suspended in
500 mL TSM, incubated with 50 mg lysostaphin for 15 minutes at
37uC for 15 minutes. 10% TCA was added and samples were
incubated on ice for 10 min. All samples were centrifuged and
washed with 1 mL ice-cold 100% acetone. Samples were air dried
and solubilized in 75 mL sample buffer (4% SDS, 50 mM Tris-
HCl, pH 8.0, 10% glycerol, and bromophenol blue).
Scanning electron microscopy
Staphylococcal strains were grown to mid-log phase (OD600
0.5), washed twice and suspended in PBS to a final OD600 1.
Bacteria were mixed with EDTA-chelated rabbit plasma (1:1) and
incubated for 15 minutes. Samples were fixed for 60 minutes in
2% glutaraldehyde in phosphate buffered saline (PBS) at room
temperature onto freshly prepared poly-L-lysine coated glass
coverslips. Samples were washed twice with PBS and subsequently
serially dehydrated by consecutive incubations in 25% and 50%
ethanol/PBS, 75% and 90% ethanol/H2O, 26 100% ethanol,
followed by 50% ethanol/hexamethyldisilazane (HDMS) and
finally with 100% HDMS. After overnight evaporation of HDMS
at room temperature, samples were mounted onto specimen
mounts (Ted Pella, Inc.) and coated with 80% Pt/20% Pd to 8 nm
using a Cressington 208HR Sputter Coater at 20mA prior to
examination with a Fei Nova NanoSEM 200 scanning electron
microscope. The SEM was operated with an acceleration voltage
of 5 kV and samples were viewed at a distance of 5 mm.
Protein purification
E. coli BL21(DE3) harboring expression vectors containing coa,
vwb,o rclfA were grown at 37uC and induced with 1 mM IPTG
after two hours. Three hours following induction, cells were
centrifuged at 7,0006g, suspended in column buffer (0.1 M Tris-
HCl, pH 7.5, 0.5 M NaCl) and lysed in a French pressure cell at
14,000 lb/in
2. Lysates were subjected to ultracentrifugation at
40,000 6g for 30 min and the supernatant was subjected to Ni-
NTA chromatography, washed with column buffer containing
10 mM imidazole, followed by elution with 500 mM imidazole.
Eluates were dialyzed against PBS. To remove endotoxin, 1:100
Triton-X114 was added and the solution was chilled for 10 min,
incubated at 37uC for 10 min, and centrifuged at 13,0006g. This
was repeated twice. Supernatant was loaded onto a HiTrap
desalting column to remove remnants of Triton-X114. Purity was
verified by SDS-PAGE analysis and Coomassie Brilliant Blue
staining.
Rabbit antibodies
Protein concentration was determined using a BCA kit (Pierce).
Purity was verified by SDS-PAGE analysis and Coomassie
Brilliant Blue staining. Six month old New-Zealand white female
rabbits were immunized with 500 mg protein emulsified in CFA
(Difco) for initial immunization or IFA for booster immunizations
on day 24 and 48. On day 60, rabbits were bled and serum
recovered for immunoblotting or passive transfer experiments. For
antibody purification, recombinant His6-Coa [12], His6-vWbp
[12], or His6-ClfA (5 mg) [36] was covalently linked to HiTrap
NHS-activated HP columns (GE Healthcare). This antigen-matrix
was then used for affinity chromatography of 10–20 ml of rabbit
serum raised against Coa [12], vWbp [12] or ClfA at 4uC.
Charged matrix was washed with 50 column volumes of PBS,
antibodies eluted with elution buffer (1 M glycine pH 2.5, 0.5 M
NaCl) and immediately neutralized with 1 M Tris-HCl, pH 8.5.
Purified antibodies were dialyzed overnight against PBS, 0.5 M
NaCl at 4uC.
Agglutination assay
Overnight cultures of staphylococcal strains were washed in
1 mL 0.85% NaCl and suspended to a final concentration of
OD600 4.0 in 1 mL. Bacteria were incubated with 1:500 Syto9
(Invitrogen) for 15 minutes, washed with 1 mL 0.85% NaCl, and
suspended in 1 mL saline. Bacteria were mixed 1:1 with EDTA-
chelated rabbit plasma (Becton, Dickinson) on a glass microscope
Figure 7. Additive protective effects of direct thrombin
inhibitors and ClfA-specific antibodies against S. aureus sepsis.
(A) Survival of cohorts of BALB/c mice (n=15) treated with saline (mock)
or dabigatran (Dbg) followed by intravenous inoculation with S. aureus
Newman (wt), clfA or clfA (pClfA) variants. Data are representative of
three independent experiments. (B) Survival of cohorts of BALB/c mice
(n=15) treated with saline (mock) or Dbg and passively immunized
(5 mg?kg
21) with affinity-purified antibodies against V10 or ClfA.
Animals were challenged by intravenous inoculation with S. aureus
Newman. Statistical analysis was assessed with the logrank test: mock-
V10 vs. mock-ClfA, P,0.001; Dbg-mock vs. Dbg-ClfA, P, 0.001. Data are
representative of three independent experiments. (C) Half-maximal IgG
titer of a-V10 or a-ClfA in serum of passively immunized mice (n=5)
was determined by ELISA. Blood was drawn on day 0, six hours post-
immunization and at day 10, when the experiment was terminated.
doi:10.1371/journal.ppat.1002307.g007
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images captured on an Olympus Provis microscope using a 406
objective. For quantification of agglutination, plasma and bacteria
were inoculated onto polystyrene C-Chip disposable hemocytom-
eter slides (IN-CYTO). Brightfield images from sixteen fields of
view were taken of bacterial strains using a Nikon TE2000 U with
a2 0 6 objective. To determine the degree of agglutination, the
Threshold Function in ImageJ software was used to convert the
image into a binary image, in which staphylococci are black and
the background is white. The mean intensity of the image was
measured. The average mean intensity of S. aureus Newman in
saline without plasma was subtracted from all values and percent
agglutination was calculated by normalizing all mean intensity
values to S. aureus Newman in plasma. To assess the inhibitory
affect of antibodies on agglutination, affinity-purified antibodies
were incubated with staphylococci to a final concentration of
3 mM for 10 minutes prior to mixture with plasma. To assess the
inhibitory affect of argatroban on agglutination, argatroban was
diluted 1:10 and 1:100 in plasma and incubated for 10 minutes
prior to mixture with bacteria. Percent agglutination was
measured compared to bacteria in plasma without argatroban.
For experiments using S. aureus N315 and MW2, agglutination was
measured as percent change in OD550 following two hours
incubation of bacteria with saline containing argatroban (1 mg/
mL), plasma, or plasma containing argatroban (1 mg/mL). Error
bars represent standard error of the mean from at least three
independent experiments to ensure reproducibility.
Sepsis
Overnight cultures of staphylococcal strains were diluted 1:100
into fresh TSB and grown until they reached an OD600 of 0.4.
Bacteria were centrifuged at 7,000 6g, washed, and suspended in
the one-tenth volume of PBS. Six week-old female BALB/c mice
(n=15) (Charles River) were injected retro-orbitally with
1610
8 CFU (S. aureus Newman, MW2, and N315) or
5610
7 CFU (S. aureus USA300) suspensions in 100 ml of PBS. Mice
were monitored for survival over 10 days. To enumerate
staphylococcal load in heart tissue twelve hours post-infection, mice
were euthanized by CO2 asphyxyation and hearts were removed
during necropsy. Heart tissue was homogenized in PBS, 0.1%
Triton X-100. Serial dilutions of homogenate were spread on TSA
and incubated for colony formation. The bacterial load in organ
tissue was analyzed in pairwise comparisons between wild-type and
mutant strains with the unpaired two-tailed Student’s t-test. For
histopathology, mice infected with S. aureus were euthanized
12 hours after infection. Hearts were removed during necropsy
and fixed in 10% formalin for 24 hours at room temperature.
Tissues were embedded in paraffin, thin-sectioned, stained with
hematoxylin and eosin, and examined by light microscopy to
enumerate pathological lesions per organ. Data were analyzed in
pairwise comparisons between wild-type and mutant strains with
the unpaired two-tailed Student’s t-test. For immunohistochemical
analysis, thin-sectioned heart tissues were stained with polyclonal
antibodies against mouse prothrombin (Haematologic Technolo-
gies) or mouse fibrinogen (Haematologic Technologies).
Figure 8. Direct thrombin inhibitors and ClfA-specific antibodies increase the time-to-death of MRSA sepsis in mice. (A) Agglutination
of methicillin-resistant S. aureus isolates N315 or MW2 in plasma in the presence or absence of argatroban (Agb). Average and standard error of the
means were calculated from at least five independent measurements and statistical significance was assessed with the Student’s two-tailed t-test:
*P,0.05, ***P,0.0001. (B) Affinity-purified rabbit IgG specific for ClfA (a-ClfA) or the plague protective antigen V10 (a-V10) was analyzed for its ability to
prevent agglutination of MRSA strains N315 and MW2 in plasma. Average and standard error of the mean were calculated from 16 fields of view from
two independent experiments. Statistical significance of antibody effects compared to a mock treated control was assessed with the Student’s two-
tailed t test: ***P,0.001. (C) Survival of cohorts of BALB/c mice (n=15) treated with saline (mock) or Dbg and passively immunized (5 mg?kg
21)w i t h
affinity-purified antibodies against V10 or ClfA. Animals were challenged by intravenous inoculation with MRSA strain N315. Statistical analysis was
assessed with the logrank test: mock-V10 vs. mock-ClfA, not significant; mock-V10 vs. Dbg-ClfA, P,0.05; mock-ClfA vs. Dbg-ClfA, P,0.05; Dbg-mock vs.
Dbg-ClfA, P,0.01. Data arerepresentative of two independent experiments. (D) Survival of cohorts of BALB/c mice (n=15) treated as described in panel
(C) and challenged by intravenous inoculation with MRSA strain MW2. Statistical analysis was assessed with the logrank test: mock-V10 vs. mock-ClfA,
not significant; mock-ClfA vs. Dbg-ClfA, P,0.001; Dbg-mock vs. Dbg-ClfA, P,0.001. Data are representative of two independent experiments.
doi:10.1371/journal.ppat.1002307.g008
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MaxSorb 96-well ELISA plates (Nunc) were coated with human
fibrinogen (Sigma) overnight. Wells were washed and solutions of
PBS or alpha-thrombin (Innovative Research), 100 nM in 1%
sodium-citrate/PBS were added for one hour at room tempera-
ture to generate fibrinogen and fibrin wells respectively. As
controls, the same conditions were generated in Eppendorf tubes.
Following incubation with or without alpha-thrombin, samples
were centrifuged at 13,000 6g for 10 min and supernatants were
recovered. The sediment was dissolved in 8 M urea. Running
buffer (3 M urea, 4% SDS, 10% BME) was added 1:1. Proteins in
supernatants and pellets were separated by SDS-PAGE (15%) and
stained with Coomassie Brilliant Blue to analyze soluble fibrinogen
in the supernatant fraction and fibrin in the sediment. Purified
recombinant ClfA in 1% sodium-citrate was added at increasing
concentrations to 96-well plates and incubated for one hour.
Samples were incubated with polyclonal anti-ClfA (1:1,000) to
detect bound-ClfA followed by goat anti-rabbit-HRP (1:10,000).
The wells were developed using an OptEIA kit (BD Lifesciences)
and absorbance at 450 nm was measured. Non-linear regression
assuming one-site saturation kinetics was performed using
GraphPad Prism.
Active immunization
Three week-old BALB/c mice (n=10) were injected with 50 mg
protein emulsified in 100 ml complete Freund’s adjuvant. Eleven
days post vaccination these mice were boosted with 50 mg protein
each emulsified in 100 ml incomplete Freund’s adjuvant. On day
21, mice were injected with 1610
8 CFU of S. aureus challenge
strains.
Passive transfer of antibodies
Six hours prior to infection, six week old BALB/c mice (n=15)
were injected intraperitoneally with specific rabbit antibodies
affinity-purified on ClfA- or V10-coupled resin (control IgG
specific for the LcrV plague antigen) at a dose of 5 mg/kg body
weight. Control mice (n=5) that received the same antibody via
passive transfer were anesthetized and bled retro-orbitally at the
time of infection and again at the end of the experiment. Blood
was collected using micro-hematocrit capillary tubes (Fisher) in Z-
Gel microtubes (Sarstedt). Tubes were centrifuged at 8,000 6g for
three minutes, and serum was collected. Antibody titer was
measured by ELISA as previously described [27].
Coagulase activity
Purified recombinant Coa or vWbp (100 nM) were mixed with
human prothrombin (Innovative Research) in 1% sodium-citrate/
PBS. After an initial reading, fibrinogen (3 mM) (Sigma) was added
and conversion of fibrinogen to fibrin was measured as an increase
in turbidity at 450 nm in a plate reader (BioTek) at 2.5 min
intervals. As controls, the enzymatic activity of human alpha-
thrombin (Innovative Research) or prothombin alone were
measured. Argatroban (200 ng, Novaplus) was added to reactions
prior to the addition of fibrinogen.
Dabigatran etexilate treatment
Dabigatran (Boehringer Ingelheim) tablets were dissolved in
0.9 N saline and doses of 10 mg/kg in 100 mL were administered.
Mice (n=15) were injected intraperitoneally starting 24 hours
prior to infection and continuing every twelve hours during the
course of the infection. Control mice received injections of 0.9 N
saline. To measure dilute thrombin time, mice (n=5) received
saline or dabigatran treatment and were euthanized by CO2
asphyxiation at the time of infection. Blood was drawn by cardiac
puncture, diluted in sodium-citrate (1%), centrifuged at 1,500 6g
for 5 minutes, and plasma diluted in pooled fresh human plasma
1:6. Thrombin time was measured on a STA-R analyzer
(Diagnostica Stago).
Supporting Information
Figure S1 Direct thrombin inhibitors and their effect on
in vitro and in vivo coagulation. (A) Conversion of fibrinogen
to fibrin by human alpha-thrombin was measured in the presence
or absence of 200 ng argatroban. Human prothrombin was
incubated alone as negative control. One arbitrary unit is defined
as A450*100. Error bars represent standard deviation of triplicate
experiments. (B) Dilute thrombin time was measured for plasma
from mice treated with saline (mock) or Dabigatran-etexilate (Dbg)
on the day of infection or on day 10 following infection. Each
symbol represents a blood sample from a single mouse. Horizontal
lines indicate mean thrombin time for the cohort. Statistical
significance was determined by two-tailed Student’s t-test:
*P,0.01, **P,0.001.
(PDF)
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